Haemonetics Co. (NYSE:HAE) EVP Sells $218,975.00 in Stock

Haemonetics Co. (NYSE:HAE) EVP Anila Lingamneni sold 2,305 shares of the firm’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $95.00, for a total transaction of $218,975.00. Following the sale, the executive vice president now directly owns 12,295 shares of the company’s stock, valued at approximately $1,168,025. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Haemonetics Stock Performance

Haemonetics stock traded down $1.95 during mid-day trading on Wednesday, reaching $93.25. The company’s stock had a trading volume of 911,085 shares, compared to its average volume of 458,956. The firm has a market cap of $4.74 billion, a price-to-earnings ratio of 37.91, a PEG ratio of 2.23 and a beta of 0.34. The business has a 50 day moving average price of $83.59 and a 200-day moving average price of $82.81. The company has a current ratio of 2.92, a quick ratio of 1.76 and a debt-to-equity ratio of 0.91. Haemonetics Co. has a twelve month low of $70.74 and a twelve month high of $97.13.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, February 8th. The medical instruments supplier reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.10. The firm had revenue of $336.20 million during the quarter, compared to the consensus estimate of $320.84 million. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. The firm’s revenue was up 10.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.85 earnings per share. Sell-side analysts predict that Haemonetics Co. will post 3.95 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on HAE. Barrington Research reissued an “outperform” rating and set a $105.00 price target on shares of Haemonetics in a research report on Friday, April 12th. TheStreet downgraded shares of Haemonetics from a “b-” rating to a “c+” rating in a research report on Thursday, February 29th. Finally, StockNews.com downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd.

Hedge Funds Weigh In On Haemonetics

A number of hedge funds have recently added to or reduced their stakes in HAE. ProShare Advisors LLC lifted its stake in Haemonetics by 4.7% in the first quarter. ProShare Advisors LLC now owns 11,490 shares of the medical instruments supplier’s stock valued at $981,000 after buying an additional 516 shares during the last quarter. Isthmus Partners LLC lifted its stake in Haemonetics by 168.5% in the first quarter. Isthmus Partners LLC now owns 48,038 shares of the medical instruments supplier’s stock valued at $4,100,000 after buying an additional 30,150 shares during the last quarter. Headlands Technologies LLC bought a new stake in Haemonetics in the first quarter valued at $114,000. Quantbot Technologies LP lifted its stake in Haemonetics by 2,101.6% in the first quarter. Quantbot Technologies LP now owns 14,068 shares of the medical instruments supplier’s stock valued at $1,201,000 after buying an additional 13,429 shares during the last quarter. Finally, Texas Permanent School Fund Corp lifted its stake in Haemonetics by 1.4% in the first quarter. Texas Permanent School Fund Corp now owns 44,447 shares of the medical instruments supplier’s stock valued at $3,794,000 after buying an additional 613 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.